Abstract:Xin Yao, 1 Qingyu Wang, 1 Changge Han, 1 Jiaojiao Nie, 1 Yaotian Chang, 1 Lipeng Xu, 1 Bingya Wu, 1 Jingtian Yan, 1 Zhiyuan Chen, 1 Wei Kong, 1, 2 Yuhua Shi, 1 Yaming Shan 1, 2 1 National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, Jilin, 130012, People's Republic of China; 2 Key Laboratory for Molecular Enzymology and Engineering, The Ministry of Education, School of Life Sciences, Jilin University, Changchun, Jilin, 130012, People's Republic of China Correspondence: Yaming Shan, School of Life Sciences, Jilin University, 2699 Qianjin Street, Changchun, Jilin, 130012, People's Republic of China, Tel +86 133 2446 4361, Email Introduction: Broadly neutralizing antibodies (bNAbs) have the ability to neutralize a considerable breadth of genetically diverse human immunodeficiency virus (HIV) strains. Passive immunization can potentially provide protection against HIV infection in animal models. However, the direct antibody infusion effect is limited due to the short half-life and deficient immunogenicity of the antibody. As an alternative strategy, we propose the use of nano viral vectors, specifically the adeno-associated virus (AAV), to continuously and systematically produce bNAbs against HIV. Methods: Plasmids expressing bNAbs PG9, PG16, 10E8, and NIH45-46 antibodies were constructed, targeting three different epitopes of HIV. Additionally, the bNAbs gene mediated by rAAV8 was administered to generate long-term expression with a single injection. We established both single and combined immunization groups. The neutralizing activity of antibodies expressed in mice sera was subsequently evaluated. Results: The expression of bNAbs in BALB/c mice can last for > 24 weeks after a single intramuscular injection of rAAV8. Further studies show that neutralization of the HIV pseudovirus by sera from co-immunized mice with rAAV8 expressing 10E8 and PG16 was enhanced compared with mice immunized with 10E8 or PG16 alone. Conclusion: The prolonged expression of neutralizing antibodies can be maintained over long periods in BALB/c mice. This combined immunization is a promising candidate strategy for HIV treatment. Graphical Keywords: AAV delivery, HIV therapy, passive immunotherapy, combined immunotherapy Graphical The envelope glycoprotein (Env) of the human immunodeficiency virus (HIV) is the only virus-encoded protein present on the virion surface. The precursor of HIV Env is gp160, which is cleaved by furin into a heterodimer consisting of surface glycoprotein gp120 and transmembrane glycoprotein gp41. 1 Functional Env manifests as a trimer of gp120-gp41 heterodimers on the surface of infectious virions. 2 gp120 binds to cellular proteins CD4 and CCR5/CXCR4, whereas gp41 mediates the fusion between the virus and the host cell membrane. 3 Broadly neutralizing antibodies (bNAbs) are capable of recognizing a myriad of HIV-1 strains, including those less susceptible to surface alterations, and effectively decrease HIV-1 levels in the human body by inhibiting their replication. 4 These antibodies play a crucial role in preventing the virus from invading target cells, finalizing intracellular assembly, and releasing new viral particles. Furthermore, they increase viral clearance via phagocytosis 5 and eradicate infected cells through an FcγR-dependent mechanism. 6 Neutralizing antibodies also inhibit HIV-1 cell-to-cell spread. 7 The analysis of these antibodies revealed four major vulnerable sites of the Env virus, namely, the CD4 binding site (CD4bs), 8 gp120 interface trimerization glycan-dependent epitopes on variable loop 1 and variable loop 2 (V1/V2) on body apex 9 or variable loop 3 (V3), 10 and the membrane proximal outer region (MPER) of gp41. 11 Long-term treatment of HIV-1 infection necessitates repetitive injections due to the antibodies' short half-life within the body. 12 Adeno-associated virus (AAV) vectors exhibit potential as gene vectors for treating HIV-1 infection owing to their desirable gene delivery properties, nonpathogenic nature, and lack of immunotoxicity. 13,14 Moreover, utilizing the self-complementary double-stranded DNA form of the vector genome facilitates faster expression dynamics. 15 AAV vectors can be further optimized by engineering and fine-tuning viral capsids to enhance their transmission properties. 16 To date, at least 18 preclinical and clinical rAAV studies have been conducted related to HIV-1 res -Abstract Truncated-

A stably expressed llama single-domain intrabody targeting Rev displays broad-spectrum anti-HIV activity.

Inhibition of HIV-1 replication by nanobodies targeting tetraspanin CD9

Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration

Rev-free HIV-1 gene delivery system for targeting Rev-RRE-Crm1 nucleocytoplasmic RNA transport pathway

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies

Alpaca-derived nanobody targeting the hydrophobic pocket of the HIV-1 gp41 NHR broadly neutralizes HIV-1 by blocking six-helix bundle formation

A VH1-69 Antibody Lineage from an Infected Chinese Donor Potently Neutralizes HIV-1 by Targeting the V3 Glycan Supersite.

Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys.

Expression of a Functional B Cell Receptor with the Specificity of VRC01, a Broadly Neutralizing Antibody Against HIV (159.8)

Suppression of viral rebound by a Rev-dependent lentiviral particle in SIV-infected rhesus macaques

Short CDRL1 in intermediate VRC01-like mAbs is not sufficient to overcome key glycan barriers on HIV-1 Env

Persistence of VRC01-resistant HIV-1 during antiretroviral therapy

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.

Cell-based and Cell-Free Firefly Luciferase Complementation Assay to Quantify Human Immunodeficiency Virus Type 1 Rev-Rev Interaction

A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope

Combined Nano-Vector Mediated-Transfer to Suppress HIV-1 Infection with Targeted Antibodies in-vitro

Viral resistance to VRC01-like antibodies with mutations in loop D and V5 from an HIV-1 B′ subtype infected individual with broadly neutralization activity

Super Potent Bispecific Llama VHH Antibodies Neutralize HIV via a Combination of gp41 and gp120 Epitopes

Tandem Bispecific Neutralizing Antibody Eliminates HIV-1 Infection in Humanized Mice

HIV broadly neutralizing antibody escapability drives the therapeutic efficacy of vectored immunotherapy

ABX464: a good drug candidate instead of a magic bullet